Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, CA 90095, USA.
J Alzheimers Dis. 2013;36(4):613-31. doi: 10.3233/JAD-130485.
The rapidly rising prevalence and cost of Alzheimer's disease in recent decades has made the imaging of amyloid-β deposits the focus of intense research. Several amyloid imaging probes with purported specificity for amyloid-β plaques are currently at various stages of FDA approval. However, a number of factors appear to preclude these probes from clinical utilization. As the available "amyloid specific" positron emission tomography imaging probes have failed to demonstrate diagnostic value and have shown limited utility for monitoring therapeutic interventions in humans, a debate on their significance has emerged. The aim of this review is to identify and discuss critically the scientific issues contributing to the extensive inconsistencies reported in the literature on their purported in vivo amyloid specificity and potential utilization in patients.
近年来，阿尔茨海默病的患病率和治疗费用迅速上升，使得淀粉样蛋白-β 沉积的成像成为研究的焦点。目前有几种据称对淀粉样蛋白-β 斑块具有特异性的淀粉样蛋白成像探针处于 FDA 批准的不同阶段。然而，有许多因素似乎使这些探针无法在临床上得到应用。由于现有的“淀粉样蛋白特异性”正电子发射断层扫描成像探针未能显示出诊断价值，并且在监测人类治疗干预方面的应用有限，因此对其意义的争论已经出现。本综述的目的是确定并批判性地讨论导致文献中报道的它们在体内淀粉样蛋白特异性和在患者中潜在应用的广泛不一致的科学问题。
